Lupkovics Géza, Kenéz András, Németh Zoltán, Motyovszki Akos, Takács István, Papp Elõd
Department of Cardiology, Zala County Hospital, Zalaegerszeg, Hungary.
Coron Artery Dis. 2008 Sep;19(6):421-3. doi: 10.1097/MCA.0b013e328304a243.
Restenosis is the most common disadvantage of percutaneous coronary interventions. The incidence of restenosis can be lowered with the use of stents. After the use of stents, 'in-stent' restenosis can occur. To avoid it drug-eluting stents were developed, but the occurrence of stent thrombosis is higher than observed in case of bare-metal stents. Endeavor is a new zotarolimus-eluting stent developed to reduce the stent thrombosis.
In a prospective study we aimed to follow-up our patients regarding the incidence of in-stent restenosis, stent thrombosis, and clinical end points after Endeavor stent implantation.
Endeavor stents have been implanted in patients undergoing coronary angiography with the following indications: complex lesions susceptible to restenosis and after recanalization of chronic total occlusions.
Endeavor stent implantations were successfully performed in 99 patients and has been successful in 98% of cases, two stents could not be implanted because of technical difficulties. Significant restenosis was observed in eight patients (8.1%). Subacute stent thrombosis (within 10 days) occurred in two patients (2.0%). Any late stent thrombosis was not observed.
Our registry affirmed the results of the Endeavor I trial in a population with more severe and longer coronary stenosis. We can conclude that the Endeavor stent is suitable for implantation in complex, longer coronary lesions. Our long-term follow-up data do not prove those opinions which prefer bare-metal stent implantation in all patients because of the late adverse events of the drug-eluting stents.
再狭窄是经皮冠状动脉介入治疗最常见的弊端。使用支架可降低再狭窄的发生率。使用支架后，可能会发生“支架内”再狭窄。为避免这种情况，研发了药物洗脱支架，但支架血栓形成的发生率高于裸金属支架。安珂（Endeavor）是一种新的佐他莫司洗脱支架，旨在减少支架血栓形成。
在一项前瞻性研究中，我们旨在随访接受安珂支架植入术后患者的支架内再狭窄、支架血栓形成发生率及临床终点情况。
安珂支架已植入有以下指征的接受冠状动脉造影的患者：易发生再狭窄的复杂病变以及慢性完全闭塞病变再通后。
99例患者成功植入安珂支架，成功率为98%，2例因技术困难未能植入。8例患者（8.1%）出现明显再狭窄。2例患者（2.0%）发生亚急性支架血栓形成（10天内）。未观察到任何晚期支架血栓形成。
我们的登记研究证实了安珂I试验在冠状动脉狭窄更严重且病变更长的人群中的结果。我们可以得出结论，安珂支架适用于植入复杂、较长的冠状动脉病变中。我们的长期随访数据并未证实那些因药物洗脱支架的晚期不良事件而主张在所有患者中优先植入裸金属支架的观点。
